Samsung Epis Holdings: The Story of Korea's Biosimilar Giant

I. Introduction & Episode Roadmap (12 min)

On the morning of November 24, 2025, two tickers appeared on the Korea Exchange where one had stood the previous month. One was the familiar 삼성바이오로직스 Samsung Biologics, the contract development and manufacturing organization that spent a decade building large-scale biologics plants in Songdo, west of Seoul. The other was new: 삼성에피스홀딩스 Samsung Epis Holdings, ticker 0126Z0, an investment holding company whose primary asset was a single wholly owned subsidiary called 삼성바이오에피스 Samsung Bioepis.¹

The split took barely six months from announcement to listing. Samsung Biologics disclosed the plan in May 2025, filed its prospectus in August, cleared regulatory review in September, and won 99.9% shareholder approval at an extraordinary general meeting on October 17.¹ Existing shareholders received shares in both entities at a ratio of roughly 0.65 to 0.35, calculated on net asset book value.² No shareholders were bought out or cashed out. The company divided itself along operational boundaries created by customer conflicts.

That boundary forms the core of the company's story. For thirteen years, Samsung operated two businesses with inherently conflicting models. One manufactured proprietary biologic drugs under contract for global pharmaceutical companies. The other developed biosimilar versions of those same companies' high-revenue drugs as patents expired. Multinational drugmakers such as Roche, Pfizer, Bristol Myers Squibb, and Merck were asked to hand manufacturing processes for their primary therapies to the corporate parent of a direct biosimilar competitor. Samsung Biologics Chief Financial Officer Ryu Seung-ho acknowledged the limitation when the split was announced, stating that despite significant effort, the company "could not fully eliminate client concerns simply through governance mechanisms."²

What investors inherited on that November morning was a biosimilar operation that generated a record 1.672 trillion Korean won in revenue in 2025—roughly $1.15 billion—across eleven approved biosimilars referencing ten distinct biological molecules sold in more than forty countries.³⁴ The portfolio includes biosimilars referencing major biologics such as Humira, Enbrel, Remicade, Herceptin, Avastin, Lucentis, Eylea, Soliris, and Stelara, alongside pipeline development for a Keytruda biosimilar. Management's stated target for 2030 includes twenty commercialized biosimilars, one novel drug candidate entering clinical trials annually, and research into peptide delivery platforms through a new subsidiary, Epis NexLab.⁵

Investors also inherited a structural paradox.

In the biosimilar industry, expanding volume often accelerates price erosion. Gaining market share typically requires price concessions, and price levels decline over time. Samsung Bioepis' quarterly market research indicates that average selling prices in the United States decline by about 52% within five years of the first biosimilar entering a drug class, and by up to 77% in mature product categories.⁶ In Europe, seventeen of twenty-eight surveyed countries mandate discounts averaging 28% against the reference drug before biosimilar competition begins, while government tender systems frequently award full market volume to a single lowest bidder.⁷ Consequently, commercial success depends primarily on maintaining low unit costs rather than product differentiation.

The bullish investment thesis holds that Samsung Bioepis can operate as a low-cost survivor by applying 삼성전자 Samsung Electronics' yield-focused manufacturing discipline to biological processing. By building a broad multi-specialty biosimilar portfolio, the company aims to amortize clinical development costs across multiple molecules. The bearish thesis views biosimilars as a commodity market with severe pricing pressure, where proposed expansions into novel drug development represent unproven diversification attempts with mixed historical execution across the broader sector.

Public markets reflect this debate. The stock reached a high of ₩773,000 on January 2, 2026, after dropping to a low of ₩329,000 two days after listing. By August 28, 2026, it closed at ₩373,500, giving the holding company a market capitalization of approximately ₩9.3 trillion.⁸ A drop of over 50% from its peak within eight months highlights ongoing investor evaluation of the company's long-term margin trajectory.

Six main themes define this analysis: the origins of Samsung Group's strategic move into biopharmaceuticals alongside its memory chip business; the architecture of the 2012 joint venture with Biogen; the commercial friction between discounted biosimilars and the U.S. pharmacy benefit manager model; the $2.3 billion buyout of Biogen's stake; the corporate split designed to address customer conflicts of interest; and whether manufacturing efficiency in biosimilars can translate into proprietary drug discovery.

That transition from biosimilar manufacturing to drug discovery represents the central variable for long-term valuation. Understanding Samsung's position requires examining the corporate strategy established in 2010, when the group sought new growth drivers beyond electronics.

Subscribe on LinkedIn

↑ Back to Top

II. The "Second Semiconductor" Ambition: Samsung Group's Bio Genesis (2010–2012) (20 min)

In May 2010, executive leadership across Samsung's affiliate companies met with Chairman 이건희 Lee Kun-hee to announce a major strategic initiative. The group committed KRW 23.3 trillion over the following decade across five new growth sectors—solar cells, rechargeable batteries for hybrid vehicles, LEDs, medical devices, and biopharmaceuticals—targeting KRW 50 trillion in annual revenue from these ventures by 2020 and the creation of 45,000 jobs.⁹¹⁰

The strategic rationale reflected structural pressures at the parent company. Samsung Electronics was performing strongly, but its earnings depended heavily on memory semiconductors and mobile handsets—two cyclical, capital-intensive markets subject to rapid commoditization. Lee's diagnosis was that existing profit centers would eventually mature, requiring Samsung to establish a "second semiconductor" business characterized by high entry barriers, multi-decade demand growth, and scale manufacturing economics that leveraged the group's core engineering strengths.

The initial capital allocation revealed a stark contrast between Samsung's original priorities and its eventual commercial outcomes. Of the KRW 23.3 trillion earmarked in 2010, biopharmaceuticals received the second-smallest commitment at KRW 2.1 trillion, while LED technology was allocated KRW 8.6 trillion, solar cells KRW 6 trillion, and hybrid-vehicle batteries KRW 5.4 trillion.⁹ By 2014, Samsung affiliates had abandoned their solar initiatives amid low-cost competition from Chinese manufacturers.¹¹ A decade later, in October 2024, Samsung Electronics announced a phased exit from the LED business.¹² The group's two largest new investments failed to deliver, leaving its smallest capital allocation to emerge as its primary strategic success.

This track record illustrates the realities of corporate portfolio management, where multiple venture bets yield selective successes. While portfolio diversification is standard corporate strategy, it differs from narratives framing Samsung's biopharmaceutical entry as prescient capital allocation. The group's expansion into biologics succeeded despite receiving far less initial capital than its underperforming ventures.

The strategic push into biopharmaceuticals was driven by an impending wave of patent expirations. First-generation monoclonal antibody therapies—including Remicade, Enbrel, Herceptin, Humira, and Avastin—were approved in the late 1990s and early 2000s and generated tens of billions of dollars in combined annual sales. As their core patents approached expiration throughout the 2010s, a major commercial opportunity opened for biosimilar development.

Replicating a biological drug differs fundamentally from manufacturing a conventional chemical generic. A small-molecule generic possesses a simple, fully defined chemical structure that can be precisely synthesized and validated as identical. In contrast, a biologic is a complex protein hundreds of times larger, cultivated in living mammalian cells inside bioreactors. Because living cells serve as the production system, slight variations in cell lines, nutrient feeds, temperature, oxygen transfer rates, or harvest timing alter protein folding, charge distribution, and glycosylation patterns. Consequently, exact identical copies do not exist; regulators evaluate biosimilars based on extensive analytical characterization and clinical trials to ensure that minor structural variations do not impact clinical performance.

This distinction explains why the industry uses the term biosimilars rather than generics, and why the primary entry barrier rests on biomanufacturing precision rather than synthetic chemistry. Developing a biosimilar requires high-yield cell lines to ensure economic viability, tight process controls to maintain batch consistency, and continuous comparability testing against reference products, which themselves undergo minor manufacturing drifts over time.

Conceptually, biomanufacturing mirrors memory semiconductor production through its high capital intensity, strict yield requirements, compounding process efficiencies, and zero tolerance for batch deviation. That parallel formed the intellectual foundation of Samsung's biopharmaceutical bet. Yet a key structural difference separates the two models: in memory chips, the cost and yield leader can set price floors to capture market share, whereas in biosimilars, pricing constraints are set by government tenders and formulary negotiations, limiting the extent to which manufacturing cost leads to market control.

Samsung was also not the pioneer in biosimilars, even within South Korea. Domestic competitor 셀트리オン Celltrion, established by a former Daewoo Motor executive without Samsung's capital resources, began developing an infliximab biosimilar in the mid-2000s. In June 2013, the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of Remsima—the world's first monoclonal antibody biosimilar—leading to full marketing authorization that September.¹³ A mid-sized Korean firm had established the regulatory precedent ahead of both global pharmaceutical incumbents and Samsung.

Celltrion's success demonstrated that European regulators would approve complex biosimilars developed by South Korean companies. However, it also meant Samsung entered the sector behind an established domestic competitor, making rapid execution a primary operational focus.

Samsung possessed substantial capital, engineering capabilities, and facility construction expertise, but lacked experience in clinical trial management, global regulatory filings, and commercial drug distribution. To bridge these operational gaps, Samsung required an experienced global partner—a search that concluded in February 2012.

↑ Back to Top

III. Building the Biosimilar Machine: The Biogen Joint Venture & Rapid Pipeline Scaling (2012–2018) (25 min)

The deal that established Samsung Bioepis in February 2012 appeared modest on paper: a $300 million joint venture, with Samsung Biologics contributing $255 million for an 85% stake and Biogen Idec contributing $45 million for 15%.¹⁴ However, the strategic significance lay in the operational asymmetry between the two partners.

Samsung provided long-term capital and an industrial mindset centered on manufacturing yield curves. Biogen contributed capabilities that Samsung could not rapidly build internally: clinical development expertise for biological therapies, established relationships with European regulatory authorities, and a sales network already distributing neurology drugs to hospitals that bought biosimilar anti-TNF therapies. Crucially, Biogen also secured an option to increase its equity stake up to 49.9%—a low-cost call option on Samsung's execution.

To lead the venture, Samsung appointed 고한승 Christopher Hansung Ko, a Korean-American holding a doctorate in genetics who had worked in the U.S. biotechnology sector before joining Samsung's new-business planning team. Ko directed Samsung Bioepis for thirteen years, becoming the longest-serving chief executive of any Samsung Group affiliate by the time of his departure.¹⁵ Early in his tenure, Ko made an aggressive operational choice: rather than developing a single biosimilar to validate the model sequentially, Samsung Bioepis launched five parallel clinical programs targeting major blockbuster drugs.

In financial terms, a single biosimilar development program typically required $100 million to $200 million and six to eight years before generating revenue. Pursuing five molecules simultaneously represented a capital commitment approaching $1 billion against regulatory frameworks that were still evolving in 2012. Independent biotech firms or venture-backed companies were generally forced to stage capital deployment sequentially. Samsung absorbed the multi-program expenditure because its cost of capital reflected the broader group's balance sheet, and because establishing early market presence ahead of domestic rivals like Celltrion and Western generic drugmakers took priority over short-term returns.

This strategy illustrated how scale functions as a structural barrier in biopharmaceuticals. The core advantage stemmed less from unit manufacturing costs per gram—where differences among major producers remained modest—than from the capacity to fund multiple development programs at once. Spreading fixed clinical and regulatory costs across a broad pipeline reduced the risk that a single clinical failure would imperil the enterprise. Samsung was not necessarily superior at producing any individual molecule; rather, it was structurally positioned to pursue more targets simultaneously.

Commercial validation arrived on January 14, 2016, when the European Commission approved Benepali, an etanercept biosimilar referencing Enbrel. Benepali became the first Enbrel biosimilar approved globally and the first subcutaneous anti-TNF biosimilar approved in Europe.¹⁶ Approvals followed for Flixabi (referencing Remicade) later that year and Imraldi (referencing Humira) in 2017, which launched across Europe in October 2018 following a patent settlement with AbbVie.

Europe served as an effective initial market due to the structure of its single-payer healthcare systems. When national health authorities select treatments, the payor and decision-maker are aligned, eliminating intermediate rebate structures and complex co-pay dynamics. Single-payer systems can transition volume rapidly when cost savings are available; for example, Denmark shifted virtually its entire etanercept volume to Benepali through a single tender. By the time Biogen evaluated exercising its call option, quarterly European sales of Benepali and Flixabi combined reached $128 million.¹⁷

However, rapid adoption in European single-payer markets presented dual consequences for long-term economics.

While early market uptake validated Samsung's manufacturing standards and regulatory filings, single-winner tender models created steep price erosion over consecutive contracting cycles. Samsung Bioepis highlighted these commercial pressures in a July 2025 policy whitepaper, noting that aggressive price competition in Europe frequently drives manufacturers out of the market entirely, and recommending multi-winner tenders alongside market-based pricing instead of mandatory discount mandates.⁷ The policy position reflected an ongoing industry tension: market share gains in single-payer regions often coincided with declining unit margins.

During this growth phase, the company also made its initial attempt to diversify beyond biosimilars into novel drug discovery—a historical precedent relevant to evaluating its subsequent pipeline goals. In August 2017, Samsung Bioepis entered a risk-sharing strategic partnership with 武田薬品工業 Takeda to co-fund and co-develop novel biologic therapies, beginning with SB26 (also designated TAK-671), an ulinastatin-Fc fusion protein targeting severe acute pancreatitis.¹⁸ A Phase 1 clinical trial in healthy volunteers began in August 2018, with initial results anticipated by the third quarter of 2020.¹⁹

In the eight years following the start of that Phase 1 study, Samsung Bioepis disclosed no Phase 2 initiation, Phase 3 data, regulatory filings, or commercial revenue associated with SB26 or the broader Takeda collaboration. Furthermore, the asset was omitted from the pipeline presented at the J.P. Morgan Healthcare Conference in January 2026, where management described SBE303 as its first novel candidate to reach clinical development.⁵ While the company did not publish a formal discontinuation notice, the track record indicates that its inaugural novel drug partnership yielded a single early-stage asset without recorded clinical advancement. Consequently, management's renewed emphasis on proprietary drug discovery builds on a mixed historical baseline.

By 2018, the joint venture had achieved its original mandate: bringing three anti-TNF biosimilars to the European market, establishing follow-on oncology and ophthalmology programs, and building a growing revenue stream. These operational milestones set the stage for Biogen's decision regarding its equity option.

↑ Back to Top

IV. Consolidation & The $2.3B Buyout: Decoupling from Biogen (2018–2022) (22 min)

The option granted to Biogen in 2012 represented one of the most critical structural terms in the venture's corporate history.

The underlying mechanics reflected a distinct joint-venture structure. Biogen initially contributed $45 million for a 15% equity stake in the $300 million venture. As Samsung Biologics funded ongoing clinical development programs over subsequent years, Biogen elected not to match the capital injections, allowing its equity holding to dilute to roughly 5.4% by 2018.¹⁷ However, the call option was structured independently of Biogen's diluted equity level. It granted Biogen the right to expand its stake up to 49.9% by paying its proportional share of Samsung's cumulative historical investment at original cost rather than prevailing market valuation.

On June 29, 2018, following European market entry for three biosimilar products and with additional filings pending, Biogen exercised the option.¹⁷ The transaction closed that November, with Biogen paying KRW 759.5 billion—approximately $677 million—for the additional shares.²⁰ Internal valuations by Samsung Biologics had previously estimated the market value of that equity block at slightly over $2 billion.¹⁷ Through the structure, Biogen executed a favorable call option backed by six years of Samsung's capital deployment, raising its profit share on the European anti-TNF portfolio to 75% and its U.S. share to 25%.¹⁷

This revenue-sharing arrangement ultimately set the baseline for the expensive buyout Samsung executed four years later.

The same period also involved regulatory scrutiny regarding Samsung's accounting valuation of the asset. In 2015, Samsung Biologics altered the accounting treatment of its stake in Samsung Bioepis, reclassifying the subsidiary in a manner that increased its carrying value by approximately KRW 4.5 trillion and shifted prior loss-making years into reported net profits shortly before Samsung Biologics' 2016 initial public offering.²¹

In November 2018, South Korea's 증권선물위원회 Securities and Futures Commission ruled that this reclassification constituted an intentional violation of accounting standards. The regulator imposed an KRW 8 billion fine, referred the case to state prosecutors, and initiated a trading suspension and delisting review that sharply reduced Samsung Biologics' market capitalization.²¹²²

Legal proceedings ultimately resolved in Samsung's favor. Executive leadership, including 이재용 Lee Jae-yong, was acquitted of related financial charges in February 2024, and on July 17, 2025, the Supreme Court dismissed the prosecution's final appeal.²³²⁴ The courts concluded that evidence was insufficient to establish illegal conduct regarding the 2015 accounting modifications and corporate restructuring.

Assessing disclosure quality and corporate governance requires examining both dimensions. While Samsung secured full legal acquittal after extended litigation, the administrative enforcement actions and trading suspension highlighted how external regulators scrutinized internal asset valuations. For institutional investors evaluating Samsung Epis Holdings, this background underscores the importance of assessing historical balance-sheet reporting alongside current valuation metrics.

On January 27, 2022, Samsung Biologics initiated one of the largest corporate acquisitions in South Korean biopharmaceutical history.

Samsung Biologics agreed to acquire Biogen's 49.9% stake for up to $2.3 billion, completing the transaction on April 20, 2022.[^25]²⁵ The payment structure was staged, comprising approximately $1.0 billion in cash at closing, $812.5 million on the first anniversary, $437.5 million on the second anniversary, and up to $50 million in performance-contingent milestone payments.[^25] Samsung also transferred a portion of its own treasury shares as consideration. For Biogen, the sale represented an exit from a non-core business asset; for Samsung, it secured full ownership of underlying operating cash flows ahead of commercial product launches in the U.S. market.

At a total purchase price of $2.3 billion for a 49.9% holding, the implied equity value of Samsung Bioepis stood at approximately $4.6 billion. Measured against 2021 annual revenue of roughly $1 billion, the transaction valued the company in line with publicly traded biosimilar peers on forward sales multiples, representing a full market price for outright operational control.

Management argued that consolidating full ownership would secure unencumbered cash flows by eliminating the profit-sharing terms that assigned 75% of European anti-TNF earnings to Biogen.

However, operational execution faced immediate market headwinds. After Samsung committed $2.3 billion in 2022, its primary U.S. product—the Humira biosimilar Hadlima—launched in July 2023 into a commercial landscape where manufacturing cost advantages did not readily yield immediate sales volume. Simultaneously, the mature European anti-TNF portfolio entered a phase of intensifying price declines driven by competitive tendering. Consequently, Samsung acquired full exposure to European cash flows just as mature product margins contracted and U.S. commercial channels introduced unexpected friction.

Subsequent financial performance does not indicate value destruction, as Samsung Bioepis continued to generate annual revenue growth behind newer commercial launches referencing ustekinumab, eculizumab, aflibercept, and denosumab, where full equity ownership yields complete economic capture. Nevertheless, the strategic payback period proved longer than initial projections implied, as structural U.S. rebate mechanisms delayed expected cash flow realization. The ultimate return on investment remains dependent on whether cumulative operating cash flows from post-2022 product launches fully recover the buyout price over the medium term.

Understanding that delay requires examining the dynamics encountered when introducing a biosimilar priced 85% below its reference biologic into the U.S. market, where list-price reductions alone do not guarantee commercial adoption.

↑ Back to Top

V. The Commercial Battlefield: Hadlima, PBM Rebate Walls, & Price Erosion (35 min)

On July 1, 2023, Hadlima went on sale in the United States at a list price of $1,038 per carton of two pre-filled pens or syringes. The reference product, Humira, carried a list price of $6,922.62 for the same carton.²⁶ An 85% discount. In almost any other industry, that is not competition; that is a demolition.

Nothing happened.

Not literally nothing — Hadlima generated $142 million of Organon revenue in 2024, its first full year.²⁷ But against a molecule that had been the best-selling drug on earth, and against nine competing biosimilars all launching into the same opening, the aggregate result was one of the most instructive commercial failures in modern pharmaceutical history. A year into the wave, Humira had lost roughly 4% of its U.S. market share to the entire biosimilar field combined.²⁸

To understand why, you have to understand the machine sitting between an American drug and an American patient.

In the U.S., most prescription drugs are not bought by patients or even by insurers directly. They are bought through pharmacy benefit managers — three of which, CVS Caremark, Express Scripts and OptumRx, control the overwhelming majority of covered lives. A PBM decides which drugs sit on a health plan's formulary, and it is compensated partly through rebates paid by manufacturers off the list price. The higher the list price, the larger the rebate, and the larger the absolute dollars flowing to the intermediary.

Now run the arithmetic that Samsung ran, and then run the arithmetic the PBM ran. Samsung's product had a list price of about a thousand dollars and, being already cheap, almost no room to pay a rebate. AbbVie's product had a list price near seven thousand dollars and could pay an enormous rebate while still netting more per prescription than Samsung's entire list price. From the plan's perspective, the rebated Humira might well cost less than the cheap biosimilar. From the PBM's perspective, it definitely paid better. AbbVie also bundled: access to its other products was, in practice, tied to keeping Humira in place.

This is the rebate wall, and it is the single most important thing to understand about this company's largest market. Samsung Bioepis brought a manufacturing-cost weapon to a contracting fight. The weapon was excellent. It was aimed at the wrong target.

Samsung and Organon tried to solve it two ways. First, formulation: Hadlima launched in both a high-concentration citrate-free presentation — matching the version of Humira the vast majority of American patients actually used — and a low-concentration version, so that no formulary could exclude it on technical grounds. Second, interchangeability. On May 27, 2025, the FDA designated Hadlima's autoinjectors and high-concentration pre-filled syringe as interchangeable with Humira, making Hadlima interchangeable with all Humira presentations and allowing pharmacists in most states to substitute it without calling the prescriber.²⁹

Interchangeability is genuinely valuable and genuinely oversold. It removes a friction; it does not remove a contract. If a plan's formulary does not list the biosimilar, the pharmacist's legal ability to substitute is irrelevant. This is the general lesson that recurs throughout this business: a regulatory designation is a permission, not a customer.

So what finally moved the market? Not the biosimilars. The PBMs.

In April 2024, CVS Caremark removed Humira from its major national commercial formularies in favor of Hyrimoz, supplied through Cordavis — an entity CVS itself had established. New prescriptions for Hyrimoz went from a few hundred a week to several thousand within a fortnight.³⁰ By mid-2024 Humira's share had fallen to roughly 82%, with biosimilars at about 18%; Hyrimoz alone held around 13%, and the nine other adalimumab biosimilars shared less than 5% between them.³⁰ The wall came down when the wall's owner decided to knock it down, and the value went to the entity doing the knocking.

Samsung Bioepis drew the obvious conclusion and joined the other side. In November 2024 it signed a private-label distributor agreement with Quallent Pharmaceuticals, a subsidiary of Cigna, to supply unbranded ustekinumab.³¹ In October 2025 it signed a private-label arrangement with CVS Caremark for its denosumab biosimilar referencing Prolia.³² These deals surrender brand identity and, presumably, a meaningful slice of gross margin. They buy the only thing that matters in this market: shelf space.

The strategy worked in market-share terms. Samsung Bioepis' own quarterly U.S. market report showed adalimumab biosimilars at 60% share as of February 2026 — though the company disclosed plainly that the jump reflected the inclusion of private-label sales in the calculation beginning that year.³³ By March 2026, the FDA had approved 92 biosimilars across 20 molecules, 67 of them launched.³³

It also created a legal problem that remains live. Johnson & Johnson sued Samsung Bioepis in the District of New Jersey on February 24, 2025, alleging the Quallent supply arrangement breached the July 2023 settlement and licence agreement that had permitted Pyzchiva's U.S. entry.³¹ The district court denied J&J a preliminary injunction, and the Third Circuit affirmed on April 14, 2026 — but the reasoning matters more than the outcome. The courts found J&J likely to succeed on the merits of its breach-of-contract claim, and denied the injunction only because lost market share in a complex market could be compensated with money.³¹³⁴ The underlying case continues. Investors should read that as an unquantified contingent liability attached to the company's most successful U.S. access strategy, not as a win.

Now the verdict on the original claim — that an 85% discount plus interchangeability would deliver dominant U.S. share. The history rejects the strong version outright. It does not reject a narrower version: a low-cost manufacturer with a broad portfolio can reach American patients at scale, but only by becoming a supplier to the intermediaries rather than a competitor to them, and only by giving up brand and margin to do it. That is a real business. It is not a moat. The KPI that will confirm or falsify the revised claim is not biosimilar market share — it is Samsung Bioepis' realized revenue per unit in the U.S., which the company does not disclose, because PBM rebates and private-label pricing are confidential.

Europe tells the same story in a different accent. The tender-driven erosion described earlier compounds year after year on mature molecules, and it shows up in partner numbers even when it is masked in Samsung's own. Organon's Renflexis, the infliximab biosimilar Samsung supplies, fell 8% in 2025 to $251 million on competitive pricing pressure; Ontruzant, the trastuzumab biosimilar, fell 30% to $99 million.²⁷ Those are the mature molecules of the first wave, doing exactly what mature biosimilars do.

The consolidated picture for 2025 was better than that, and the reason is worth getting right because it is widely misreported. Samsung Bioepis posted record revenue of KRW 1.672 trillion, up 9%, while operating profit fell 14% to KRW 375.9 billion.³ Read naively, that looks like margin collapse under price deflation. It was not. The decline came from a drop in one-time R&D milestone payments recognized in the prior year. Strip milestones out, and product sales grew 28% to KRW 1.626 trillion and operating profit more than doubled — up 101% to KRW 330.8 billion.³⁴ The underlying product business was healthier in 2025 than the headline suggested.

The honest caution runs the other way in 2026. Samsung Bioepis grew first-quarter revenue 14% year over year, then went backwards in the second quarter — revenue down 2% to KRW 392.2 billion and operating profit down 4%.³²³⁵ Half-year growth landed at 6%, against management's stated 2026 target of more than 10% growth in global biosimilar sales.³ One weak quarter is not a trend. But it is precisely the shape of quarter that price erosion produces: volume holding, revenue not.

That treadmill — grow the portfolio faster than the prices fall — is the operating reality of this company. What changed in 2025 was not the treadmill. It was who was standing on it.

↑ Back to Top

VI. The 2025 Structural Split: Why Samsung Biologics Spun Off Samsung Epis Holdings (25 min)

Every contract manufacturer relies on a single essential asset: trust. A pharmaceutical company handing over its cell lines, process parameters, and yield data is surrendering the core intellectual property of a therapy worth billions of dollars. The contract development and manufacturing organization (CDMO) industry operates on strict firewalls, comprehensive audit rights, and the foundational assumption that the manufacturer has no commercial interest in a molecule beyond producing it.

Samsung Biologics spent thirteen years asking its global customers to accept an exception to that rule.

By 2024, the company counted 17 of the world's top 20 pharmaceutical companies as clients.¹ Every one of those clients knew that Samsung Biologics' parent group owned a separate unit dedicated to developing biosimilar copies of their originative drugs as patents expired. Samsung's response relied on organizational safeguards: separate legal entities, dedicated facilities, isolated data systems, and strict contractual firewalls. On paper, the boundaries appeared robust.

In practice, structural separation proved insufficient to dispel client reservations. When Samsung Biologics disclosed its corporate restructuring in May 2025, Chief Financial Officer Ryu Seung-ho acknowledged that despite extensive governance controls, client concerns could not be fully eliminated through internal mechanisms alone.² The statement conceded a fundamental commercial reality: the perception of a conflict of interest created ongoing business friction that administrative firewalls could not engineer away.

From a client's perspective, selecting a contract manufacturer for a multibillion-dollar drug involves risks beyond intellectual property theft. Corporate clients weigh operational trade-offs, such as bioreactor suite allocation during peak demand, batch prioritization during production crises, and the reality that manufacturing margins directly fund a corporate group developing competing biosimilars. In a market where Samsung Biologics competes against Lonza, WuXi Biologics, and Fujifilm Diosynth for major commercial contracts, even a minor competitive hesitation can redirect long-term manufacturing agreements elsewhere.

Consequently, Samsung executed the corporate separation it had deferred for a decade.

The transaction was structured as a horizontal split rather than a divestment. Samsung Biologics carved out its investment and subsidiary management division into a standalone entity, which assumed 100% ownership of Samsung Bioepis. Existing shareholders received equity in both companies. Under the split allocation, Samsung Biologics retained approximately KRW 9.9 trillion in net assets—roughly $7.4 billion—while the new holding company received about KRW 3.4 trillion, or $2.5 billion, with minimal debt.² Because no cash changed hands, no control premium was levied, and no minority buyout occurred, the split passed with 99.9% shareholder support rather than becoming another chapter in Korea's long history of contested chaebol restructurings.¹

The shareholder vote highlighted a departure from historical South Korean chaebol restructurings, which frequently drew criticism for consolidating family control through asset transfers at disputed valuations—most notably during the 2015 merger at the center of subsequent legal scrutiny involving Lee Jae-yong. By executing a pro-rata distribution based on net asset book value and listing both entities simultaneously, Samsung structured a transparent split that treated minority shareholders equitably in its mechanics.

However, market performance following the listing reflected ongoing valuation debate. After reaching a peak of ₩773,000 within six weeks of its November 2025 debut, Samsung Epis Holdings dropped by more than half by late August 2026.⁸ Part of that volatility stemmed from initial trading technicalities, such as forced index rebalancing and a lack of historical analyst coverage. More fundamentally, public markets were tasked with pricing a standalone biosimilar developer without the steady revenue buffer of a high-margin CDMO business.

The split also tested the longstanding rationale for co-locating the two operations. For over a decade, Samsung argued that housing CDMO manufacturing and biosimilar R&D on the same Songdo campus created vertical integration benefits, enabling shared bioprocessing know-how and guaranteed production capacity. Severing that structure demonstrated that whatever operational synergies existed, they were outweighed by the commercial discount the dual model imposed on the CDMO business. Because Samsung Biologics reported KRW 4.557 trillion in 2025 revenue—roughly 2.7 times Samsung Bioepis' total—the group optimized for the larger asset, leaving Samsung Epis Holdings as the party that lost the integration argument.³⁶

Operationally, Samsung Bioepis continues to manufacture its therapies through commercial supply contracts with Samsung Biologics. While arm's-length agreements maintain baseline production, the loss of internal affiliation alters soft operational dynamics, including priority during capacity constraints, informal process collaboration, and executive escalation.

In exchange, the spin-off granted Samsung Epis Holdings operational autonomy and a distinct equity currency. Chief Executive Officer Kyung-Ah Kim noted upon launch that independent decision-making enables targeted capital allocation once decisions no longer route through a parent with different priorities.³⁷ As a standalone listed entity with an independent board, Samsung Epis Holdings can issue equity, pursue acquisitions, and finance novel-drug R&D without competing internally against a CDMO's capacity expansion program. Whether that strategic flexibility is executed effectively represents the core question for long-term investors.

↑ Back to Top

VII. Segment Deep-Dive & Economics: Biosimilar Engines vs. Epis NexLab Optionality (25 min)

Beneath the holding-company wrapper, Samsung Epis Holdings operates as two distinct components: a commercial biosimilar producer generating steady but price-constrained cash flows, and an early-stage laboratory that yields no revenue.

Segment 1: Samsung Bioepis — the engine

The commercial subsidiary accounts for the group's entire operational business. As of management's January 2026 J.P. Morgan Healthcare Conference presentation, Samsung Bioepis had eleven approved biosimilars referencing ten distinct biological molecules marketed across more than forty countries, generating 100% of holding company revenue.⁵

The commercial portfolio divides into four distinct therapeutic clusters, each exhibiting contrasting market dynamics.

Immunology represents the company's largest and most established segment, but also its most crowded. Benepali reached a decade of European commercialization in 2026 while maintaining a leading share in the etanercept market.³² Flixabi and Imraldi complete the European anti-TNF franchise. In the United States, Hadlima leads the immunology portfolio alongside Pyzchiva—the ustekinumab biosimilar referencing Stelara—which launched on February 24, 2025, through commercial partner Sandoz.³⁸ Ustekinumab represents a critical test case: internal market research from Samsung Bioepis indicated that biosimilar adoption for ustekinumab accelerated significantly faster than for adalimumab, despite both operating under pharmacy-benefit structures—suggesting that U.S. commercial channels adapted quickly after initial friction during the Humira rollout.⁶

Oncology serves as a cautionary example of mature product dynamics. Ontruzant (referencing Herceptin) and Aybintio (referencing Avastin) face intense competition from multiple generic entries. As reflected in partner Organon's financial reports, product maturity exerts relentless pressure on top-line revenue. Unlike pharmacy-benefit therapies, oncology biosimilars are administered in hospitals and clinics under medical-benefit coverage. Consequently, they compete directly on average sales price through transparent institutional purchasing, driving rapid initial volume adoption followed by steep, continuous price erosion.

Ophthalmology presents the clearest illustration of commercial partner risk. Byooviz, approved on September 20, 2021, marked the first ophthalmology biosimilar cleared by the U.S. Food and Drug Administration.³⁹ Opuviz, referencing Eylea, received FDA approval in May 2024, followed by the European launch of a 40-milligram-per-milliliter vial presentation in May 2026.³⁵ However, commercial execution in the U.S. stumbled when initial distributor Biogen, which held exclusive North American rights under a November 2019 contract, notified Samsung Bioepis in October 2024 that it was terminating the agreement.⁴⁰ Samsung Bioepis was forced to re-tenant the franchise, partnering with Harrow in July 2025 to commercialize both therapies following a complete transition of rights by year-end 2025.⁴¹ As a result, Byooviz underwent a commercial relaunch in the U.S. in 2026—five years after securing its historic regulatory approval.

This sequence highlights a fundamental operational reality across the biosimilar sector. While Byooviz represented a scientific breakthrough, distributor dislocation delayed commercial traction by half a decade. Being first to secure regulatory approval provided prestige, yet yielded minimal market advantage without stable, long-term commercial distribution.

Hematology and rare diseases represent the company's newest and economically most compelling segment. Epysqli, an eculizumab biosimilar referencing Soliris, launched in the U.S. on April 7, 2025, through partner Teva at a modest 30% discount to the reference drug's list price.⁴² Unlike mass-market immunology products requiring 85% price cuts, rare-disease biologics cater to small patient populations managed by specialized treatment centers. With fewer competitors entering the space, pricing dynamics resemble branded pharmaceuticals rather than commoditized generics. Denosumab—launched in Europe under the brand names Obodence and Ospomyv in December 2025 and expanded into the U.S. through a private-label arrangement with CVS Caremark—occupies similarly favorable commercial territory.³³²

These market dynamics carry direct strategic implications for valuation. Samsung Bioepis' long-term operating margins will depend less on total portfolio volume than on launching products into underserved, low-competition niches. Commercializing twenty therapies in crowded classes yields lower returns than maintaining eight in limited-competitor markets. While management targets twenty commercialized biosimilars by 2030, the decisive metric for investors is how many of those targets will encounter fewer than three competing entries.⁵

Assessing unit economics requires navigating significant disclosure gaps. Samsung Epis Holdings does not publish revenue breakdown by therapeutic area, gross margins, or R&D expenditures as a percentage of sales in its quarterly reporting, while Samsung Bioepis operated as an unlisted subsidiary prior to the late 2025 split. Reported consolidated operating margins have historically ranged in the low-to-mid 20% span. Furthermore, commercial partnerships with Organon, Sandoz, Teva, Harrow, and Biogen allocate substantial economic value to external distributors, while U.S. private-label arrangements surrender additional margin to pharmacy benefit managers. By focusing primarily on development, manufacturing, and supply while outsourcing global sales, Samsung Bioepis mitigates commercial infrastructure costs but establishes a structural ceiling on gross profitability.

Financial reporting introduces an additional variance requiring scrutiny. In the first half of 2026, Samsung Bioepis generated KRW 230.6 billion—approximately $165 million—in standalone operating profit, whereas parent company Samsung Epis Holdings reported consolidated operating profit of KRW 149.3 billion.³⁵ This creates an unexplained gap of roughly KRW 81 billion between the operating subsidiary and the holding company over a six-month period. While holding-company administrative overhead, funding for newly formed units, and standard accounting consolidation adjustments likely account for the difference, management has not provided a detailed reconciliation. For an investment thesis predicated on margin durability, this transparency gap remains a critical area for investor inquiry.

Segment 2: Epis NexLab — the option

Established on November 10, 2025, as a wholly owned subsidiary, Epis NexLab is chartered to build next-generation biotechnology platforms, with an initial mandate to develop long-acting peptide delivery systems capable of yielding multiple therapeutic candidates.⁴³⁴⁴ The unit currently possesses no commercial products, revenue, or clinical-stage assets. Its initial public initiative was a research collaboration with South Korean firm G2GBIO to co-develop a long-acting microsphere delivery technology.⁴⁵

The commercial rationale for peptide delivery systems addresses significant clinical demand. Extending dosing schedules for peptide therapies—such as GLP-1 receptor agonists—from weekly to monthly administration represents a high-value technological modification across global metabolic markets. In tandem, management disclosed that Samsung is evaluating internalizing linker and payload technologies for antibody-drug conjugates (ADCs) to reduce reliance on third-party licensing.⁴⁶

Outside Epis NexLab, Samsung Bioepis advanced its proprietary oncology pipeline by securing FDA clearance in December 2025 for SBE303, its inaugural novel antibody-drug conjugate targeting Nectin-4 across urothelial, lung, and breast cancers. A global Phase 1 trial initiated patient dosing in March 2026.⁵³² A second candidate, SBE313, remains in pre-clinical evaluation in partnership with Phrontline Biopharma.³² Management has pledged to advance one novel candidate into clinical trials annually, targeting another ADC entry for 2027.⁴⁶

In biopharmaceutical design, an antibody-drug conjugate functions as a targeted payload delivery mechanism: a monoclonal antibody binds to specific proteins expressed on tumor cells, releasing a potent cytotoxic agent directly into target tissues. Samsung Bioepis contends that fourteen years of monoclonal antibody development provide a strong technical foundation for engineering these complex constructs.

However, translating biosimilar expertise into novel drug discovery presents significant technical execution risk. Biosimilar development relies on analytical comparability against a validated reference drug with proven mechanisms and known clinical endpoints. In contrast, novel drug discovery requires validating unproven biological targets and demonstrating superior clinical efficacy in human trials. While analytical and manufacturing capabilities overlap between the two disciplines, they diverge at the early stage where clinical candidate attrition is highest.

Samsung's assertion that biosimilar manufacturing precision can translate into proprietary discovery remains unvalidated by historical performance. As established during the 2017 Takeda collaboration, the company's prior attempt at novel drug co-development yielded a single Phase 1 asset that saw no recorded clinical progression over eight years. While SBE303 employs a distinct modality and management structure, past execution suggests treating Epis NexLab and the internal ADC pipeline as early-stage options rather than established core competencies. Key milestones confirming progress would include a clean Phase 1 dose-escalation readout for SBE303 advancing into Phase 2, alongside commercial licensing agreements for Epis NexLab's delivery platforms.

Consequently, investors should view Epis NexLab and the novel drug pipeline as speculative options that carry minimal present value on current balance sheets. Capital allocation discipline surrounding these early-stage R&D initiatives will serve as a primary determinant of long-term holding-company returns.

↑ Back to Top

VIII. Management, Governance, & Capital Allocation under Kyung-Ah Kim (18 min)

On November 27, 2024, Samsung appointed 김경아 Kyung-Ah Kim as President and CEO of Samsung Bioepis, succeeding Christopher Hansung Ko, who moved to lead Samsung's Future Business Planning organization.¹⁵ The appointment marked two notable shifts: Kim became the first woman to lead a Samsung Group affiliate and brought a background in biological research rather than corporate strategy. Having spent over twenty years in biologics development, she had served since December 2021 as head of Samsung Bioepis' Development Division, managing product development across therapeutic areas.¹⁵

This leadership succession reflected changing corporate priorities. For thirteen years, Ko's mandate focused on foundational expansion: building the biosimilar pipeline, establishing regulatory capabilities, securing product approvals, and expanding into European markets. Having executed the parallel-development model that defined the company's first decade, he left behind an established commercial portfolio and European market presence.

Kim's mandate focuses on optimizing margins from an established asset base operating under continuous price erosion. Under her leadership, Samsung Bioepis expanded direct European commercialization to five products, entered the Japanese market in May 2026 through a partnership with ニプロ NIPRO, established its first overseas R&D hub in China, and expanded its collaboration with Sandoz in March 2026 to cover up to five next-generation biosimilar candidates, including SB36 referencing Entyvio.³⁵³²⁴⁷ Her tenure also encompassed guiding the company through its corporate split and public listing.

Direct European commercialization represents the most economically significant of these strategic initiatives. While distributing through commercial partners requires sharing unit revenue, direct sales allow Samsung Bioepis to retain full gross margin in exchange for funding its own commercial infrastructure. In an environment characterized by tender price cuts, margin defense requires either reducing manufacturing costs or eliminating distribution intermediaries. Although the bullish thesis for the medium term depends heavily on the financial value of this margin recapture, management has provided qualitative guidance rather than specific quantitative metrics.

Management's execution record under Kim presents an early test of guidance discipline. During the full-year 2025 earnings announcement in January 2026, management projected global biosimilar sales growth of over 10% for 2026.³ Following a strong first quarter, second-quarter revenue contracted year over year, bringing first-half growth to 6%. Management maintained its full-year outlook without adjustment in its July 2026 disclosure, with Kim describing the outcome as "solid first-half 2026 results."³⁵ Although first-half performance fell short of double-digit guidance, the full-year outcome remains open; how leadership addresses this gap in subsequent earnings reports will offer a meaningful test of corporate disclosure quality.

A broader structural transparency issue predates current management: the company does not disclose its net realized price per unit in the United States. Because U.S. pricing dynamics are governed by confidential pharmacy benefit manager rebates and private-label distribution contracts, outside investors can track overall biosimilar market share and partner revenue reports, but cannot calculate net revenue realized per patient in the company's primary growth market. While this opacity stems from U.S. pharmaceutical pricing structures rather than management withholding, it leaves a core component of long-term earning power unquantified for external analysts.

Corporate governance considerations present distinct risks for minority shareholders. 삼성물산 Samsung C&T holds approximately 43.1% of Samsung Epis Holdings, while 삼성전자 Samsung Electronics holds roughly 31.2%, giving the two Samsung Group affiliates a combined stake of nearly 75%.⁴⁸ With public float comprising only the remaining quarter, minority shareholders lack voting leverage to contest corporate actions or launch activist initiatives. Consequently, the 99.9% shareholder approval rate for the 2025 corporate split reflected controlling voting power rather than broad consensus among independent investors.

This ownership structure carries broader strategic implications. Because Samsung C&T functions as the primary vehicle for family control over Samsung Electronics, Samsung Epis Holdings operates within a broader group ownership structure. Capital allocation choices, dividend policies, and potential corporate restructurings will ultimately be determined by major shareholders whose primary financial exposure resides in other group entities, creating potential divergence between majority control priorities and minority equity interests.

In this context, the historical regulatory scrutiny surrounding Samsung Bioepis' 2015 accounting reclassification serves as an analytical reference point. Although legal proceedings concluded with full judicial acquittal, administrative actions by securities regulators highlighted past friction over asset valuation methods in a corporate structure where minority shareholders possess limited governance mechanisms. For external investors, risk mitigation depends primarily on reporting transparency and consistent quarterly operational execution rather than formal governance protections.

Capital allocation strategy presents complex trade-offs for management. Operating cash flows must simultaneously support expanding the biosimilar portfolio from eleven to twenty commercialized products by 2030, advancing one novel clinical candidate annually, and funding pre-revenue research operations at Epis NexLab. Management characterizes its novel drug development strategy as a "stepwise approach grounded in strong scientific validation" rather than short-term performance-driven development.⁴⁶ However, without a formal disclosure breaking down R&D expenditure between biosimilar development and novel drug research, evaluating the capital discipline behind these parallel commitments remains challenging.

Ultimately, the core investment question is whether Samsung Epis Holdings can build a durable competitive advantage or will operate as an efficient participant in an industry defined by ongoing price erosion.

↑ Back to Top

IX. Strategic Playbook & Competitive Moats: 7 Powers & 5 Forces (20 min)

The corporate architecture that emerged from the split is simple enough to draw on a napkin, which is exactly the point of a holding company.

graph TD
    A[Samsung Epis Holdings] --> B[Samsung Bioepis]
    A --> C[Epis NexLab]
    B --> D[Immunology: Hadlima, Benepali, Pyzchiva]
    B --> E[Ophthalmology: Byooviz, Opuviz]
    B --> F[Oncology: Ontruzant, Aybintio]
    C --> G[Novel ADCs & Peptide Delivery]

Simplicity of structure, however, is not the same as strength of position. Evaluating the business through Hamilton Helmer's 7 Powers framework reveals a company with genuine but narrow advantages operating in an industry designed to resist long-term moats.

Process Power — the strongest claim, and still conditional. Samsung Bioepis' primary structural asset is the accumulated capability to take a known biological molecule to an approved, manufacturable, and analytically comparable copy faster and with fewer failed development programs than a subscale rival. That capability rests in cell-line development, bioreactor yield optimization, and analytical methods that demonstrate biosimilarity to regulatory authorities such as the FDA and EMA. Embedded in organizational routines rather than patents, it fits Helmer's definition of process power: competitors cannot buy it turnkey, and replicating it requires years of execution.

The supporting evidence is consistent—a fourteen-year record of securing regulatory approvals across four therapeutic areas without a publicly disclosed catastrophic clinical failure, alongside a pipeline expanded to seven additional biosimilars, including candidates referencing Keytruda, Dupixent, Tremfya, Taltz, and Enhertu.⁴⁶ The SB27 pembrolizumab program offers a clear proof point: both Phase 1 and Phase 3 trials met their primary endpoints, with the confidence interval on the objective response rate ratio falling within the pre-defined equivalence margin.⁴⁹

Crucially, process power translates into economic returns only when commercial channels reward speed and reliability. Shortening development cycles and mitigating clinical risk offer significant value in a market with two competitors, but minimal advantage in a class with nine, where price levels deteriorate regardless of entry order. In this context, process power operates as a survival mechanism rather than a pricing lever.

Scale Economies — real, and the foundation of the business model. Spreading fixed clinical development and regulatory expenses across a broad portfolio reduces reliance on any single therapy. Few generic or biosimilar developers maintain the balance sheet required to fund seven parallel programs targeting blockbuster biologics, providing structural logic to management's target of twenty commercialized biosimilars by 2030.

However, scale remains contestable by well-capitalized global peers. Sandoz operates as an independent biosimilar competitor with established global distribution. Amgen funds biosimilar development alongside a high-margin proprietary pipeline. Celltrion maintains integrated manufacturing capacity and, by 2026, saw Truxima become the first South Korean biosimilar to achieve top prescription share in its molecule within the United States.⁵⁰ Competitors such as Formycon, Coherus, Biocon, and Fresenius Kabi similarly contest overlapping target classes. Scale distinguishes Samsung Bioepis from smaller regional players rather than industry leaders.

Counter-Positioning — weak, as U.S. commercial dynamics demonstrate. In theory, a low-cost biosimilar entrant counter-positions against an originator unable to cut list prices without eroding existing revenues. In practice, originator strategy relies on contractual bundling and high-rebate formulary access rather than list-price reductions. Intermediary structures neutralize the theoretical advantage. While counter-positioning functions more effectively in European tender markets, originators often match tender pricing directly, capturing cost savings for healthcare systems rather than biosimilar manufacturers.

Cornered Resource — essentially absent. Proprietary cell lines and regulatory dossiers carry substantial asset value, yet biosimilars inherently target off-patent molecules where entry barriers consist of capital and lead time rather than exclusive intellectual property. Samsung Bioepis possesses no mandatory licensed compounds—providing the strategic rationale for its proprietary drug programs, where an antibody-drug conjugate with composition-of-matter patents would mark its first genuine cornered resource.

Switching Costs, Branding, and Network Economies — negligible. Hospital pharmacies and formularies face minimal friction when transitioning between interchangeable biological therapies, reflecting regulatory design. Brand equity plays a limited role when product value centers on equivalence to a reference biologic, a reality reflected in Samsung's private-label supply agreements. Network effects are absent.

Evaluating the industry through Porter's Five Forces presents a tougher competitive reality.

Buyer power is extreme and represents the defining market force. In the United States, three major pharmacy benefit managers control access to covered patient populations while increasingly launching private-label distribution arms. In Europe, government tender authorities award volume through competitive bidding. Under both frameworks, buyers dictate pricing terms. Samsung Bioepis' policy advocacy supporting multi-winner tender structures reflects a request for purchasing authorities to moderate their bargaining power.⁷

Rivalry is intense and structurally accelerating. Expiring biologic patents consistently attract multiple global, well-capitalized competitors. The resulting market dynamics resemble high-entry-cost commodity auctions: substantial capital commitments fail to prevent margin compression once multiple entrants secure approval.

Threat of substitutes is material and persistent. The primary long-term risk to a biosimilar portfolio stems from reference-drug obsolescence. Next-generation modalities—including oral small molecules, bispecific antibodies, and targeted cell therapies—can supersede entire target classes. A pipeline focused on expiring blockbuster biologics inherently remains one technological generation behind emerging treatment paradigms.

Supplier power is moderate and newly relevant. Following the corporate split, Samsung Bioepis sources commercial manufacturing through supply contracts with Samsung Biologics, an entity no longer under common subsidiary ownership. Contractual terms remain undisclosed, and third-party CDMO capacity allocations could create operational friction during peak demand cycles.

Threat of new entrants is moderate. Capital requirements and technical expertise establish meaningful entry barriers, though emerging global developers with lower cost structures continue to enter the sector.

The analytical conclusion is clear. Samsung Epis Holdings maintains two of Helmer's seven powers in partial form while operating in an industry marked by high buyer power, intense rivalry, and an absence of switching costs. This structural profile does not preclude long-term value creation; a disciplined low-cost manufacturer operating in a growing sector can compound returns over time. However, ongoing financial performance depends on operational execution and portfolio execution rather than structural moat protections.

↑ Back to Top

X. Analysis: Bull vs. Bear Case & Material Risk Radar (18 min)

Why this company wins from here

The bull case does not require believing in a structural moat. It requires confidence in three observable operational mechanisms.

The first is portfolio breadth across an expanding market. Samsung Bioepis commercializes therapies in immunology, oncology, ophthalmology, and rare diseases, insulating the business from price decay in any single drug class. Internal market research indicates U.S. biosimilars averaged a 47% market share across launched molecules by mid-2026, with immunology biosimilars gaining roughly 25 percentage points of market penetration annually over their first five years.⁶ A developer with ten commercialized molecules participates across each of these expanding categories.

The second lever is margin recapture through disintermediation. Transitioning to direct European commercialization across five products and reclaiming U.S. ophthalmology distribution rights after Biogen's exit both convert partner margins into internal cash flow. This represents management's most direct operational catalyst, entirely within its control.

The third mechanism is the upcoming wave of high-value biosimilar targets. Ustekinumab and aflibercept remain early in their commercial lifecycles compared to mature anti-TNF therapies. Meanwhile, pembrolizumab represents the largest single biosimilar opportunity in industry history—a therapy generating over $25 billion in annual sales, with primary U.S. patent protection expiring in 2028. Samsung Bioepis has already completed Phase 3 clinical trials for its candidate.⁴⁹ Capturing even a modest share of that market under moderate price discounting would fundamentally alter the company's financial scale.

Why it may not

The bear case is equally concrete, starting with the risks inherent in portfolio expansion.

Every new high-value biologic will attract the same dense competitive field that compressed original anti-TNF margins, and rival entrants now reach market faster. Multiple well-funded competitors are advancing pembrolizumab biosimilars. Competing as one of six suppliers differs fundamentally from sharing a duopoly, and realized pricing reflects market density rather than manufacturing precision.

The commodity trap remains the central structural risk: average U.S. selling prices fall by approximately half within five years of initial biosimilar entry, with mature product categories experiencing declines exceeding 75%.⁶ To generate net revenue growth in this environment, a developer must commercialize new therapies faster than mature product prices deflate. First-half 2026 performance—showing 6% top-line growth against management's double-digit guidance, alongside a negative second quarter—provides initial empirical evidence of this treadmill effect.

Furthermore, U.S. market access remains rented rather than owned. Recent market-share gains relied heavily on private-label arrangements controlled by the same pharmacy benefit managers that historically restricted biosimilar adoption. One of these key supply deals remains embroiled in breach-of-contract litigation, where an appellate court noted the originator's likelihood of success on the merits. Intermediary access secured on these terms remains vulnerable to contract renegotiation or cancellation.

Finally, the corporate split from Samsung Biologics removed an implicit operational backstop. Samsung Bioepis no longer holds priority access to parent CDMO capacity and must fund its clinical pipeline entirely from its own operating cash flows.

The activist's questions

A skeptical institutional investor analyzing Samsung Epis Holdings would raise four unanswered questions.

First, why did approximately KRW 81 billion in operating profit dissipate between the operating subsidiary and the consolidated holding company over a six-month period, and what is the ongoing run-rate for corporate overhead and pre-revenue research at Epis NexLab? Second, how is the internal research budget allocated between biosimilar development—which carries a predictable return profile—and novel drug discovery? Third, what is the precise financial contribution of the direct European distribution model that management highlights as a key growth driver? Fourth, what is the maximum financial exposure resulting from ongoing contract litigation with Johnson & Johnson?

A broader structural question centers on corporate architecture. Investors own a holding company rather than an operating business. In South Korea, holding companies frequently trade at a discount to net asset value, and this structure pairs a cash-generating subsidiary with an unproven, cash-consuming research unit. While management asserts that a standalone holding company allows Epis NexLab to be funded without encumbering operating subsidiary cash flows, equity analysts recognize this structure as a familiar vehicle for potential conglomerate value dilution.

The current risk radar

Rebate and formulary risk represents the largest unhedgeable exposure. U.S. pharmaceutical pricing structures remain subject to regulatory flux, including proposed 340B program reforms and legislative scrutiny of pharmacy benefit manager rebate models.⁶ Reforms favoring lower net prices would benefit low-cost biosimilar producers, whereas further consolidation among major intermediaries would reduce manufacturer leverage. Samsung Bioepis remains a price-taker under either outcome.

Clinical and regulatory execution risk remains a persistent operational factor. Portfolio expansion requires consistent approvals from the FDA and European regulatory bodies; a single Complete Response Letter or facility inspection finding could defer expected revenues by multiple quarters.

Tariff and geopolitical risk shifted from an immediate threat to a deferred exposure in 2026. A U.S. executive proclamation on April 2, 2026, introduced Section 232 tariffs on patented pharmaceuticals of up to 100%, with a 15% rate for trade-partner nations including South Korea. However, the action exempted generics, biosimilars, and active biological ingredients for one year, shielding major South Korean exporters from immediate disruption.⁵¹⁵² The U.S. Department of Commerce was instructed to determine within twelve months whether to extend tariffs to generic and biosimilar imports.⁵¹ Because Samsung Bioepis manufactures in Songdo for export to the U.S. market, future tariffs would directly compress gross margins in a segment without pricing power to pass on costs. The current exemption represents a temporary reprieve rather than a permanent resolution.

Substitution and obsolescence risk operates on a multi-year horizon but poses the most fundamental threat to long-term valuation. If therapeutic standards shift toward modalities outside Samsung's manufacturing platform—such as oral small molecules, cell therapies, or bispecific constructs—the addressable universe for future biosimilars will shrink at the source.

↑ Back to Top

XI. Epilogue & Core Investment KPIs (10 min)

The story that began with a South Korean conglomerate deciding that memory semiconductors would not power growth forever has arrived somewhere its original architects might find unexpected. Samsung's biopharmaceutical bet succeeded—it stands as the single growth engine from the five sectors announced in 2010 that achieved scale, while larger commitments to solar energy and LED lighting were abandoned. Yet that success ultimately split into two companies with contrasting business models: a contract manufacturer selling high-demand production capacity, and a biosimilar developer selling price-competitive volume.

Samsung Epis Holdings operates on the biosimilar side. Over fourteen years, the company demonstrated the technical capability to target complex biological molecules, reconstruct them from cell lines, and secure approvals across major global regulatory authorities. Developing eleven commercialized biosimilars referencing ten molecules across more than forty countries represents a substantial industrial execution, completed rapidly after Celltrion established the regulatory pathway.

What remains unproven is whether this technical success translates into durable equity returns. The operating business generated record revenue in 2025 before top-line growth slowed sharply in the second quarter of 2026. Its primary market rewards intermediary contracting relationships over manufacturing precision alone, and market access in the United States has required surrendering brand identity, sacrificing gross margins, and managing ongoing breach-of-contract litigation. Its highest-margin therapies are those facing minimal competition, meaning profitability reflects molecule density rather than proprietary pricing power. Meanwhile, proposed growth drivers—including antibody-drug conjugates and peptide delivery platforms—remain early-stage options that must still demonstrate clinical and commercial viability.

This assessment reflects structural market realities rather than operational failure. Samsung Bioepis functions as a technically proficient, well-capitalized participant in an industry structured to limit excess economic rents. Whether the company outperforms that baseline depends on operational execution that must be renewed annually across every target molecule and regional tender.

Three key metrics will determine the long-term investment outcome:

Realized biosimilar sales growth against management targets. Management projected global biosimilar revenue growth of more than 10% for 2026, delivering 6% growth in the first half of the year. This metric tracks the operational treadmill by netting revenue from new product launches against ongoing price erosion across mature therapies, providing the clearest measure of whether portfolio expansion is outpacing market price deflation.

Consolidated operating margin at the holding-company level. While Samsung Bioepis' operating margin measures the performance of the core business, Samsung Epis Holdings' consolidated margin reflects actual shareholder returns after accounting for corporate overhead and pre-revenue research at Epis NexLab. The spread between the two represents the cost of funding new platform options. A widening margin gap without corresponding pipeline advancement would indicate that the holding company structure is diluting operating cash flows.

Commercial conversion of novel-drug milestones. Initial trial clearances and early Phase 1 starts represent regulatory permissions rather than commercial validation. The decisive indicators of execution are SBE303 advancing past Phase 1 dose escalation into a Phase 2 trial with defined patient endpoints, and Epis NexLab securing a platform licensing agreement with disclosed commercial terms. Given that the company's initial novel-drug collaboration in 2017 yielded a single Phase 1 asset without recorded clinical advancement, historical execution places the burden of proof on tangible trial data and signed partnership agreements rather than corporate projections.